drugset
drugset / Trial / NCT01893177

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

NCT01893177 ↗

Phase 3 Completed 110 enrolled Crucell Holland BV
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The study is to assess whether the influenza vaccine Inflexal V for season 2013/2014 fulfills the EMA requirements for re-registration of influenza vaccines.

Timeline

Start
2013-07
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Inflexal V Vaccine 0.5 ml Intramuscular

Indications

influenza